Product Launch Success: Getting It Right In Rare Disease
As we wrote in our last article, “To Ace Your Product Launch, Don’t Fail At Market Access,” launching a drug into a crowded market without understanding the market access landscape is like failing to study for a make-or-break final. Yet while inadequate patient access to a life-saving treatment is much graver than a disappointing grade, […]
To Ace Your Product Launch, Don’t Fail At Market Access
Imagine that it’s senior year of high school, and you show up to chemistry class completely unprepared for the midterm exam—a midterm that’s worth half of your grade. Instead of studying the periodic table, you spent the previous evening rehearsing your choir solo. And while extracurriculars are important, messing up a few lyrics during the […]
Will New Approaches to Medical Benefit Contracting Help Control Specialty Drug Spend?
Pharmacy benefit contracting has always been a mechanism for payers to offset the cost of small-molecule therapeutic areas. Payers have looked to manufacturers to negotiate contracts that would prevent their products from being placed on a restrictive tier, or subject them to step edits or an NDC block. But with the emergence of biologics driving […]
How Commercial Leaders Can Boost Sales Force Effectiveness
Two years of adapting to the constraints of a global pandemic has resulted in major changes to pharma companies’ commercial strategies. Now, as pandemic-related changes have started to become permanent fixtures, sales leaders are asking themselves key questions amid the shifting commercial landscape: How does my strategy need to evolve? How will it affect my […]
How Pharma Companies Can Navigate the Medical Exception Process at Launch
There are many challenges that manufacturers face when launching a new drug: Will physicians prescribe the drug? Will they have any legal issues? Will patients request the drug? How should they market and distribute it? The list goes on and on, but one of the most critical questions to answer is this: Will patients be […]
Why Pharma Companies Need a Strategy to Track Market Access in Real-Time
With payer coverage decisions around pharmaceuticals changing rapidly, simply being covered is no longer enough for getting patients on therapy quickly. Today, increasing market complexity and outsize payer influence have resulted in numerous hurdles to ensuring adequate access, from prior authorizations to step therapy to label restrictions. To succeed at launch amid these higher stakes […]